Captain T Cell secures €20 million in funding to advance its next-generation TCR-T therapies for solid tumors, led by Springboard Health Angels and Pluton Asset Holding AG.

Information on the Target

Captain T Cell, located in Schönefeld/Berlin, is at the forefront of developing pioneering T-cell therapies specifically designed to target solid tumors that are currently difficult to treat. The company specializes in creating next-generation TCR-T cells that remain active in the body for extended periods and are adept at navigating the challenging tumor microenvironment. Additionally, Captain T Cell has established an allogeneic platform that paves the way for future off-the-shelf therapies, demonstrating the potential for widespread availability of its innovative treatments.

Founded by a team of experts in immuno-oncology, Captain T Cell leverages cutting-edge technologies originally developed at the Max Delbrück Center for Molecular Medicine in Berlin. With a focus on personalized immunotherapies, their TCR-T therapies are engineered to recognize and combat cancer cells by enhancing the body's own T-cell receptors, marking a significant advancement in cancer treatment.

Industry Overview in Germany

The biopharmaceutical market in Germany is robust and continually evolving, driven by advancements in research and technology, particularly in the field of immunotherapy. Germany’s strategic investment in healthcare innovation has positioned it as a